v3.25.0.1
Consolidated Statements of Equity - USD ($)
shares in Millions, $ in Millions
Total
Common stock
Treasury Stock, Common
Additional paid-in capital
Retained earnings (accumulated deficit)
Accumulated other comprehensive loss
Noncontrolling interest
Beginning balance at Dec. 31, 2021 $ 15,436 $ 18 $ (3,143) $ 18,305 $ 3,127 $ (2,899) $ 28
Beginning balance (in shares) at Dec. 31, 2021   1,768          
Increase (Decrease) in Stockholders' Equity              
Net earnings attributable to AbbVie Inc. 11,836 $ 0 0 0 11,836 0 0
Other comprehensive income, net of tax 700 0 0 0 0 700 0
Dividends declared (10,179) 0 0 0 (10,179) 0 0
Purchases of treasury stock (1,487) $ 0 (1,487) 0 0 0 0
Purchases of treasury stock (in shares)   (10)          
Stock-based compensation plans and other 976 $ 0 36 940 0 0 0
Stock-based compensation plans and other (in shares)   11          
Change in noncontrolling interest 5 $ 0 0 0 0 0 5
Ending balance at Dec. 31, 2022 17,287 $ 18 (4,594) 19,245 4,784 (2,199) 33
Ending balance (in shares) at Dec. 31, 2022   1,769          
Increase (Decrease) in Stockholders' Equity              
Net earnings attributable to AbbVie Inc. 4,863 $ 0 0 0 4,863 0 0
Other comprehensive income, net of tax (106) 0 0 0 0 (106) 0
Dividends declared (10,647) 0 0 0 (10,647) 0 0
Purchases of treasury stock (1,978) $ 0 (1,978) 0 0 0 0
Purchases of treasury stock (in shares)   (12)          
Stock-based compensation plans and other 974 $ 0 39 935 0 0 0
Stock-based compensation plans and other (in shares)   9          
Change in noncontrolling interest 4 $ 0 0 0 0 0 4
Ending balance at Dec. 31, 2023 10,397 $ 18 (6,533) 20,180 (1,000) (2,305) 37
Ending balance (in shares) at Dec. 31, 2023   1,766          
Increase (Decrease) in Stockholders' Equity              
Net earnings attributable to AbbVie Inc. 4,278 $ 0 0 0 4,278 0 0
Other comprehensive income, net of tax 380 0 0 0 0 380 0
Dividends declared (11,178) 0 0 0 (11,178) 0 0
Purchases of treasury stock (1,703) $ 0 (1,703) 0 0 0 0
Purchases of treasury stock (in shares)   (9)          
Stock-based compensation plans and other 1,188 $ 0 35 1,153 0 0 0
Stock-based compensation plans and other (in shares)   8          
Change in noncontrolling interest 2 $ 0 0 0 0 0 2
Ending balance at Dec. 31, 2024 $ 3,364 $ 18 $ (8,201) $ 21,333 $ (7,900) $ (1,925) $ 39
Ending balance (in shares) at Dec. 31, 2024   1,765